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Abstract
Amiodarone is an anti-arrhythmic medicine used in the treatment of heart arrhythmias. Due to its long half-life, lipophilic 
structure, and accumulation in the tissues of the thyroid, liver, lung, cornea and skin, it can cause many adverse effects. 
Acute liver failure is a rare complication following the administration of amiodarone. Several dozen cases of acute liver 
failure after administration of amiodarone have been described. Its mechanism is not yet clearly known. It has been 
suggested that emulsifier of the intravenous form of the drug (polysorbate 80) could be a reason for the disorder, but 
it also occurs after oral administration. The diagnosis can be established when amiodarone results in liver failure with 
encephalopathy and blood coagulation disorders, excluding other hepatotoxic factors. The recommendations for the 
management of this disease have not yet been established. However, the prognosis is serious because high mortality 
has been observed.
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Introduction
Amiodarone is a class III anti-arrhythmic drug used to treat 
atrial fibrillation and ventricular arrhythmias [1]. It is an iod-
ine derivative of benzofuran, and its molecule contains two 
iodine atoms. It is metabolised in the liver by cytochrome 
P450 isoenzymes, where the dealkylation process takes 
place and the active metabolite desetyloamiodarone is 
formed. This causes many interactions with other drugs 
metabolised by this enzyme, such as H1 receptor antago-
nists, warfarin, acenocoumarol, statins, digitalis glycosides, 
antiarrhythmics (procainamide, disopyramide, phenytoin, 
and diltiazem), antidepressants (fluoxetine, paroxetine, 
bupropion), antibiotics from the group of macrolides and ke-
tolides, isoniazid, as well as grapefruit juice and St. John’s 
wort [2]. It is a lipophilic drug that accumulates in the liver, 
lungs, thyroid, adipose tissue, skeletal and cardiac mu-
scles, from where it is gradually released. This causes the 
possibility of side effects originating from various organs, 
which is associated with the slow elimination of the drug 
from the body. Its half-life ranges from 30 to 100 days [3].
Epidemiology
Skin reactions associated with hypersensitivity to light and 
disorders of the gastrointestinal tract are the most common 
side effects of the drug [3, 4]. About 90–100% of patients 
have amiodarone microsamples deposited in the cornea, 
which is usually asymptomatic. Ophthalmologic control is 
required only in a case of visual disturbance [4]. It can be 
a cause of optic neuritis on very rare occasions. Hypoten-
sion, bradycardia, atrioventricular block and prolongation 
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of the QT interval have been observed during intravenous 
therapy [5]. Thyroid function may be abnormal (hypo- or 
hyperthyroidism with excess iodine) with long-term oral 
administration of the drug [4]. Inflammatory or fibrotic 
lesions in the lungs have also been observed as a side 
effect of amiodarone [4].
Gastrointestinal symptoms were observed in approxi-
mately 30% of patients using amiodarone [6]. These include 
nausea, vomiting, anorexia, and mainly asymptomatic liver 
damage, with moderate elevations in aminotransferases. 
The latter affects 15–50% of patients treated with this 
drug [6]. Treatment must be discontinued in the case of 
a two-fold or three-fold increase in the activity of these 
enzymes [2]. Acute hepatic failure is a rarely described 
consequence of using the drug, the prevalence of which 
is estimated to be 1–3% [6]. A case of a patient with acute 
liver injury after the use of amiodarone was described for 
the first time in 1986 [7]. Since then, dozens of such case 
reports have appeared.
Definitions and classifications
There are several definitions of acute hepatic failure (acute 
liver failure or acute liver injury), and their common feature 
is rapid, and even fulminant, course of liver dysfunction 
leading to the development of encephalopathy. The could 
be due to toxic agents, it could be drug-induced (most 
commonly paracetamol), but also it may have viral or au-
toimmune causes particularly in people without previously 
diagnosed liver dysfunction [8], whereas drug-induced liver 
injury (DILI) is biochemical liver damage after the use of 
drugs or herbs [9].
Liver damage can be divided into two main types [10]:
 — intrinsic (predictable), usually after using the drug in 
high doses;
 — idiosyncratic (unpredictable), when damage occurs in 
a small group of patients, regardless of the dose of 
the drug, and in a way not previously seen in scientific 
research.
Part of the unpredictable reactions are allergic rea-
ctions associated with acquired or congenital hypersens-
itivity, and the remaining ones are idiosyncratic [11].
Three liver damage types have been calculated accor-
ding to the point scale (R-ratio) [12]:
R =  
activity of ALT/ALT – ULN  
        activity of ALP/ALP – ULN
where: ALT — alanine aminotransferase; ULN — upper 
limit of normal; ALP — alkaline phosphatase, and:
 — R ≥ 5 hepatocellular DILI;
 — R < 2 cholestatic DILI;
 — 2 < R < 5 mixed DILI
Amiodarone can cause any type of liver damage [9].
Pathogenesis
The mechanism of amiodarone hepatotoxicity has not 
been explained. However, clinical observations show dif-
ferent pathways after oral and intravenous administration 
[11]. Damage after oral use is explained by drug depo-
sition in tissues. Amiodarone accumulates in liposomes 
and causes damage to cellular mitochondria [11]. Acute 
liver failure after intravenous use of the drug is probably 
driven by another mechanism, as yet not fully understood. 
Initially, liver toxicity was not suggested for amiodarone 
alone, but in conjunction with polysorbate 80, which is 
used as an emulsifier in medicines, cosmetics and food 
[13]. It is part of the intravenous form of the drug, and 
its damaging effect on hepatocytes has been confirmed 
earlier in cases involving the so-called E-ferol-syndrome 
[14]. Liver damage with jaundice and renal failure was 
observed after the use of vitamin E preparations con-
taining polysorbate 80 and polysorbate 20 in neonates 
[14]. However, cases of acute liver damage following 
intravenous administration of amiodarone containing no 
preservative have also been reported [15]. Beuer et al. 
[16] hypothesised that an autoimmune mechanism of 
post-amiodarone liver damage is possible. However, it 
was not the subject of further research. In 2011, Gluck 
et al. [17] questioned the occurrence of acute hepatic 
failure after administration of amiodarane. The authors 
hypothesised that the cause of liver damage in its use is 
hypoxia caused by hypotonia or shock (so-called ischaemic 
hepatitis) [17]. This mechanism is most often related to 
older people (> 70 years of age) and to haemodynamically 
unstable patients caused by arrhythmias.
It is therefore difficult to identify one mechanism re-
sponsible for the development of acute liver damage when 
using amiodarone.
According to a literature review by Nasser [18], the de-
velopment of acute hepatic failure occurs most frequently 
over a period of several dozen hours (about 1–6 days) after 
the administration of a multiple of the standard daily doses 
of the drug (about 900 mg/day). The lowest dose after 
which liver damage has been observed was 200–600 mg 
per day [18].
Diagnosis
Diagnosis of post-amiodarone acute liver injury requires 
the finding of acute failure of this organ and the exclusion 
of other causes. An important role is played by the history 
and clinical symptoms [9].
Clinical presentation
The course of the disease is dominated by symptoms of 
liver damage, such as jaundice, nausea and vomiting, as 
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well as disturbances of consciousness typical of hepatic 
encephalopathy (from slowness of movement to hepatic 
coma) [18, 19]. There are also symptoms associated 
with enlargement of the liver in the course of its damage, 
or venous stasis caused by heart failure, with a typical 
hepatojugular reflux [18]. Due to the cause of the drug’s 
administration, cardiac arrhythmias and symptoms of heart 
failure, pulmonary oedema, peripheral oedema as well as 
abnormal blood pressure values (mainly hypotonia) have 
been observed [17, 18]. Hepatic insufficiency is often 
accompanied by kidney damage with oliguria or anuria [19].
Diagnostic tests
Laboratory tests usually show increased activity of 
aminotransferases (alanine and aspartate), increases 
in bilirubin, ammonia and lactates, prolongation of 
prothrombin time with INR increase, thrombocytopenia, 
hypoproteinemia and hypoglycaemia, as well as kidney 
damage presenting as an increase in creatinine and urea 
[15–20]. In patients with the cholestatic mechanism of 
liver damage, an increase in gamma-glutamyltransferase 
and alkaline phosphatase activity is also observed. It is 
recommended to exclude viral infections (hepatitis A, B 
and, C virus, Epstein-Barr virus, cytomegalovirus) and au-
toimmune diseases of the liver and lesions of the type of 
vasculitis [20]. It is recommended to perform toxicological 
and microbiological tests.
The serum concentration of amiodarone and its meta-
bolite desetylamiodarone can be measured [21]. However, 
no correlation has been found between increased blood 
levels of the drug and organ damage, because it is related 
to the metabolism of the drug and its tissue deposition [22]. 
The subject of the analysis is the relationship between the 
concentration of drug and its metabolites in the blood and 
thyroid damage [21]. However, there is no data showing 
the link between liver damage and the concentration of 
the drug in the blood. It may be helpful to determine the 
concentration of the drug or its metabolite in tissues [23]. 
Tsuda et al. [22] reported a case in which, after discontinu-
ation of amiodarone, a correlation was observed between 
the decrease in drug concentration and the decrease in 
transaminase activity, with a noticeable improvement in 
imaging and histopathological findings.
Imaging diagnostics
In cases of cytotoxic liver damage, the American College of 
Gastroenterology [9] recommends imaging examinations 
after laboratory tests for viral and autoimmune diseases. 
In cases of cholestatic mechanism, the diagnostic pathway 
should be started with imaging examinations [ultrasound, 
computed tomography (CT) or endoscopic retrograde 
cholangiopancreatography (ERCP)]. In the analysed cases 
of liver damage after administration of amiodarone, 
commonly used liver Doppler ultrasound often does not 
reveal any abnormalities [7, 13, 16, 20]. The enlargement 
of the liver in the course of peripheral circulation arrest 
has been repeatedly reported [14, 18]. In the course of 
ischaemic hepatitis, there are no changes in the liver in the 
ultrasound images [18]. There are more and more reports 
showing a characteristic picture in computed tomography 
of changes in hepatic liver damage [22–24]. The domi-
nant picture is diffuse elevated radiodensity of the liver 
parenchyma [22]. This is related to the accumulation of 
a drug containing iodine in the liver [2, 23]. In the studies, 
the discontinuation of the drug causes a noticeable gra-
dual decrease in the densities [23, 24]. In cases of organ 
biopsy, a CT picture correlated with the histopathological 
evaluation [22]. In the literature, there is no case of mag-
netic resonance imaging, positron emission tomography 
with CT or ERCP being performed for liver injury after the 
administration of amiodarone.
Histopathology
In the majority of reported post-amiodarone liver damage 
cases, no liver biopsy was performed. Histopathological 
examinations carried out after the death of the patient 
caused by acute hepatic injury revealed hepatonecrosis, 
indicating a toxic or ischaemic process [7, 19, 25]. Among 
patients after intravenous administration of the drug, even 
small doses, and a history of fast-developing jaundice, 
hepatonecrosis and fibrosis of the organ were observed 
in post-mortem liver samples [25]. Two very characteristic 
histopathological images of liver damage are steatosis 
[25] and phospholipidosis [26]. The characteristics of 
steatosis are comparable to the changes observed in 
alcohol abuse with Mallory bodies and neutrophilic infil-
tration [25]. Occasionally liver cirrhosis with regenerative 
nodules and developed fibrosis have been observed [22]. 
In phospholipidosis, lysosomal fat accumulation has 
been observed in the electron microscope due to the 
accumulation of amiodarone in hepatocytes lysosomes, 
and due to the blockage of enzymes that should remove 
lysosomal lipids [22, 26].
Treatment
There are no treatment guidelines because of the low 
prevalence. The base of the treatment is amiodarone 
discontinuation, patient monitoring in conditions of in-
tensive supervision or intensive care, fluids, intestinal or 
parenteral feeding, and the prophylactic use of proton-
-pump inhibitors and pressure amines if necessary [15, 
19, 27, 28]. In patients with acute renal failure, renal 
replacement therapy has been successfully used [28]. It 
is also recommended to correct the coagulation disorder 
using vitamin K or the transfusion of fresh frozen plasma 
[27]. Recently, the beneficial effects of N-acetylcysteine 
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Prognosis
High mortality in the course of acute hepatic failure resul-
ting from the use of amiodarone is well-documented in the 
literature [15, 18, 19]. However, it is impossible to precisely 
define mortality, as many cases remain unrecognised. 
A poor prognosis has been observed in cases where liver 
cell necrosis and organ fibrosis have occurred [25].
Despite the description of cases of acute hepatic failure 
after oral administration of the drug, it is a safe treatment 
with adequate control [12]. Diab et al. [33] attempted to 
determine the risk factors for acute hepatic injury after 
amiodarone administration. They showed the importance 
of previous liver damage, circulatory failure, high doses of 
the drug, hypotension in the course of arrhythmia, and the 
administration of amiodarone in the postoperative period 
after surgery including coronary artery bypass grafting. The 
influence of many other factors studied, such as male gen-
der, hypoalbuminaemia, hyperglycemia, cardiopulmonary 
resuscitation, and the occurrence of hepatitis has not yet 
been confirmed [33].
Due to the high mortality, the importance of early diagnosis 
and the discontinuation of amiodarone must be underlined.
administration has been reported [15, 29]. The drug was 
used in the scheme recommended for the treatment of 
poisoning with paracetamol, i.e. 300 mg/kg in divided 
doses over 24 hours [30].
The continuity of anti-arrhythmic therapy is an impor-
tant issue. In most of the described patients, amiodarone 
was not re-applied, rather a switch was made to other 
antiarrhythmic drugs, most commonly beta-blockers, digo-
xin and non-dihydropyridine calcium channel antagonists 
[31, 32]. For the primary prevention of sudden cardiac de-
ath in the course of ventricular arrhythmia, an implantable 
cardioverter-defibrillator or percutaneous ablation should 
be considered [22].
Attempts have been made to reintroduce the drug after 
normalisation of liver function (so-called re-challenge test). 
Even after switching to the oral form of the drug, a rene-
wed increase in aminotransferases has been observed 
[18]. There have also been reports of cases in which liver 
damage following intravenous amiodarone treatment has 
not been followed by worsening of liver function after oral 
treatment [13, 31, 32]. This supports the hypothesis that 
liver failure is influenced by factors other than amiodarone, 
e.g. polysorbate 80.
Streszczenie
Amiodaron jest lekiem antyarytmicznym powszechnie stosowanym w terapii zaburzeń rytmu serca. Ze względu na bar-
dzo długi okres półtrwania, lipofilną budowę i gromadzenie w tarczycy, wątrobie, płucach, rogówce i skórze amiodaron 
może powodować wiele działań niepożądanych. Ostra niewydolność wątroby jest rzadkim powikłaniem po jego podaniu. 
Opisano zaledwie kilkadziesiąt takich przypadków. Mechanizm uszkodzenia wątroby nie jest jeszcze dobrze poznany. 
Sugerowano szkodliwy wypływ polisorbatu 80 (konserwantu dożylnej formy leku), ale do ostrego zaburzenia funkcji wą-
troby dochodzi również po doustnym stosowaniu leku. Rozpoznanie jest ustalane, gdy po podaniu amiodaronu rozwija 
się ostra niewydolność wątroby z encefalopatią i zaburzeniami krzepnięcia krwi, po wykluczeniu udziału innych czyn-
ników hepatotoksycznych. Nie opracowano jeszcze zaleceń postępowania w tych przypadkach. Rokowanie jest jednak 
poważne, gdyż obserwowano wysoką śmiertelność.
Słowa kluczowe: amiodaron, działania niepożądane, ostra niewydolność wątroby, polekowe uszkodzenie wątroby,  
polisorbat 80
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